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Abstract 
Background: Matrix metalloproteinases (MMPs) are endopeptidases that can degrade extracellular matrix compo-
nents and affect invasiveness and aggressiveness of oral squamous cell carcinoma (OSCC). The aim of this study 
was to examine the immunohistochemical expression of MMP-2 and MMP-8 in OSCCs in patients presenting at 
the Tertiary Health facility in Nigeria
Materials and Methods: Formalin-fixed, paraffin-embedded (FFPE) OSCC samples diagnosed between the years 
2010 and 2012 were used for his study. The FFPE were processed for MMP-2 and MMP-8 using the specifications 
of the manufacturer. Two investigators reviewed the slides scoring the pattern and intensity of staining as negative 
(0), weakly positive (+1), moderately positive (+2) and strongly positive (+3). The data were analysed using ver-
sion 20 of the SPSS. The level of significance was set at P < 0.05.
Results: Twenty-five OSCC consisting of 14 (56%) males and 11 females (44%) were used. The mean age was 54.6 
± 17.9 years. A higher proportion (100%) of poorly differentiated OSCC strongly expressed MMP-2 compared with 
the well differentiated and moderately differentiated OSSC. There was no significant difference in the expression of 
MMP-2 amongst the three grades of OSCC (X2 = 2.87; p= 0.17). Only 5 (20%) OSCC cases positively expressed 
MMP-8. Moderate expression of MMP-8 was only seen in well-differentiated OSCCs. 
Conclusions: This study showed that a higher proportion of poorly differentiated OSSC strongly expressed MMP-2. 
Eighty percent of cases that express MMP-8 were females and moderate expression of MMP-8 was seen only in 
well differentiated OSCC. 
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Introduction
Oral squamous cell carcinoma (OSCC) is the most com-
mon malignant neoplasm in the oral cavity, and it is still 
regarded as a significant global public health problem 
(1). The management of OSCC most often includes sur-
gery with or without neck dissection, followed by adju-
vant radiotherapy (2). In spite of diagnostic and thera-
peutic developments, the 5-year survival rate for head 
and neck cancers has not significantly improved over the 
past decades (2,3).
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Matrix metalloproteinases (MMPs) are a family of at 
least 17 human zinc dependent endopeptidases that can 
degrade almost all extracellular matrix components (4). 
They are classified into five groups according to their 
substrate specificity: collagenases (MMP-1, -8, and -13), 
gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10), 
and membrane-type MMPs (MT-MMPs) (MMPs 14–17, 
24, and 25) and other MMPs (MMPs11, 19 and 20) (5). 
The expression of these MMPs is rapidly induced when 
active tissue remodelling is required in physiological 
and pathological conditions (5,6). It is well recognized 
that MMPs are key mediators of tumour invasion and 
metastasis because of their involvement in cell prolifera-
tion, survival, angiogenesis, and cell migration (6). 
Fan et al. (7) in a study in China had previously repor-
ted that high tumour and stromal MMP-2 and MMP-9 
expression were significantly associated with positive 
lymph node status and the overall patient survival was 
significantly shorter in patients with high tumour and 
stromal MMP-2 and MMP-9 expression. Furthermore, 
MMPs inhibitors are potential therapeutic agents in the 
management of cancers with less adverse effects and 
possible better prognosis. This present study was carried 
out to examine the immunohistochemical expression of 
MMP-2 and MMP-8 in oral squamous cell carcinoma 
cases seen at the Department of Oral Pathology, Univer-
sity College Hospital Ibadan.
Material and Methods 
Twenty-five samples of formalin-fixed, paraffin-em-
bedded (FFPE) OSCC diagnosed between the years 
2010 and 2012 were retrieved from the Department of 
Oral Pathology archives, University College Hospital, 
Ibadan.  Freshly prepared sections were stained with 
haematoxylin–eosin (H&E) and the antibody to MMP-2 
(Monoclonal CA-4001/CA719E3C, Abcam), MMP-8 
(Monoclonal 115-13D2, Abcam) using the specifications 
of the manufacturer. The sections for immunohistoche-
mistry were de-paraffinized, hydrated and then rinsed in 
phosphate-buffered solution (PBS). They were immersed 
in heat-induced epitope retrieval citrate buffer diluted 
1:10 with distilled water and incubated at 900 C for 60 
minutes. They were then placed in fresh citrate, cooled in 
water for 20 minutes and then rinsed in PBS. Positive and 
negative controls were employed for the antibodies.
Hydrogen peroxide (3%) was added to each section for 
10 minutes, and the sections were rinsed in 0.1% PBS. 
The specimens were incubated for 60 minutes with 
1:20 dilution of Abcam mouse monoclonal antibody to 
MMP-2 and MMP-8 followed by incubation with undi-
luted labelled polymer horseradish peroxidase-conjuga-
ted with anti-mouse secondary antibody for 30 min. One 
ml of diaminobenzidine solution was added to cover the 
specimen, followed by incubation in a humidity cham-
ber for 15 minutes. The sections were then immersed 
in aqueous haematoxylin and rinsed in distilled water. 
The tissue was dehydrated and subsequently rinsed with 
xylene. Distyrene plasticizer in xylene mounting fluid 
was then applied, and a cover slip placed.
Two investigators reviewed the slides scoring the pattern 
and intensity of staining as follows: negative (<10%) (0), 
weakly positive (10–25%) (+1), moderately positive (25–
50%) (+2) and strongly positive (>50%) (+3) (8). The 
data were analysed using version 20 of the SPSS. Qua-
litative data were compared using chi-squared statistics. 
Quantitative data were summarized using mean, standard 
deviation and confidence interval and compared using 
Mann-Whitney U and/or one-way analysis of variance 
test. The level of significance was set at P < 0.05.
Results
A total of 25 cases of OSCC consisting of 14 (56%) ma-
les and 11 females (44%) were included in this study. 
The age range was 10-86 years with a mean age of 54.6 
± 17.9 years. The palate was the most common site of 
occurrence with 6 (24%) cases followed by the mandible 
with 5 (20%) cases while the maxilla and lip mucosa 
both had 4 (16%) cases each and other sites such as ton-
gue, buccal mucosa, floor of mouth, maxillary antrum 
altogether accounted for 7 (20%) cases. The moderately 
differentiated OSCC with 13 (52%) cases was the most 
common grade followed by the well differentiated with 
10 (40%) cases, while the poorly differentiated OSCC 
accounted for 8% of cases (Table 1).
Table 1. Demographic and clinicopathological characteristics of 
patients.
Patients  Variables N (%)
Age 
range 10-86
Mean ± SD 54.6 ± 17.9
Gender
Male 14 (56%)
Female 11 (44%)
Site
Palate 6 (24.0)
Mandible 5 (20.0)
Maxilla 4 (16.0)
Lip mucosa 4 (16.0)
Buccal mucosa 2(8.0)
tongue 2 (8.0)
Maxillary antrum 1 (4.0)
Floor of mouth 1 (4.0)
Histological Grade of OSCC
Well 10 (40.0)
Moderately 13 (52.0)
poorly 2 (8.0)
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Table 2 shows the expression of MMP-2 in different 
grades of OSCC. Eight (80%) well-differentiated OSCC 
showed positive expression for MMP-2, 61.5% of mode-
rately differentiated OSSC showed positive expression 
while 100% of poorly differentiated OSCC showed po-
sitive expression for MMP-2. The two cases (100%) of 
poorly differentiated OSCC strongly expressed MMP-2 
while only 40% and 23.1% of the well differentiated 
and moderately differentiated OSSC strongly expressed 
MMP-2 respectively. There was however, no significant 
difference in the expression of MMP-2 amongst the 
three grades of OSCC (X2 = 2.87; p= 0.17). Also, there 
was no statistically significant difference in MMP-2 ex-
pression according to gender and site (p=0.23 and p = 
0.37 respectively Mann-Whitney U).
Tumour grade -ve (%) +1 +2 +3 Total +ve (%)
Well 2 (20.0) 3(30.0) 1(10.0) 4 (40.0) 8 (80.0)
Moderate 5 (38.5) 3(23.1) 2(15.4) 3 (23.1) 8 (61.5)
poorly 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 2 (100.0)
Table 2. Expression of MMP-2 according to histologic grade.
Only 5 (20%) OSCC cases positively expressed MMP-8 
while 20 (80%) were negative. Three (30%) well-diffe-
rentiated OSCC showed positive expression for MMP-8, 
one of the 13 (7.7%) cases of moderately differentiated 
OSSC showed positive expression while one of the two 
cases (50%) of poorly differentiated OSCC showed posi-
tive expression for MMP-8. Of the 5 cases that were po-
sitive for MMP-8, 3 (12%) mildly expressed MMP-8, 2 
(8%) moderately expressed MMP-8 while no case stron-
gly expressed MMP-8. The two cases that moderately 
expressed MMP-8 were well-differentiated OSCCs. All 
the three cases of OSCC that mildly expressed MMP-8 
strongly expressed MMP-2. Although, majority (80%) 
of the cases that expressed MMP-8 were seen in females 
there was no statistically significant difference in the ex-
pression of MMP-8 between males and female (p=0.065 
Mann-Whitney U). Figure 1 shows MMP-2 and MMP-8 
Fig. 1. Immunohistological findings for MMP2, MMP8 in oral squamous cell carcinoma. (A and B) Im-
munoperoxidase stain with hematoxylin counterstain in well differentiated squamous cell carcinoma with 
(+++) MMP-2 stain and moderately differentiated squamous cell carcinoma with (++) MMP-8 stain.
expressions in well differentiated OSCC and moderately 
differentiated OSCC respectively.
Discussion
The palate was commonest site of occurrence for OSCC 
in this study which was contrary to many previous reports 
that showed the tongue to be the most common site of 
occurrence (9- 11). However, studies from Africa (12,13) 
have shown other sites aside from the tongue to be the most 
common sites of occurrence and a study by Otoh et al. 
(14) from Nigeria which reported that the palate was com-
monest site was in agreement with this study. Although, 
the finding of a mean age of 54.6 years was in conformity 
with the fact that OSCC is more commonly seen in older 
patients especially in those above age of forty (10,12), the 
age range of 10-86 shows it can also be found in the very 
young. Previous reports have also shown that OSCC can 
occur in very young with some authors reporting  OSCC 
in children as young as 3 years of age (12,13). It is known 
that an inherited bone marrow failure syndrome, dyskera-
tosis cogenita may predispose sufferers to squamous cell 
carcinoma which usually present between the ages 5-12 
years (15). However the presence of dyskeratosis coge-
nita or any other congenital predisposing factor was not 
proven in this case.
There was a relatively higher proportion of strong ex-
pression of MMP-2 in poorly differentiated OSCC in 
this study compared to the other histologic grades. A 
study in Iran reported a positive correlation between 
levels of MMP-2 expression and histologic grades of 
OSCC (16). Similarly, in a study considering expression 
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of p53, Ki-67, MMP-2 and MMP-9 in OSCC and verru-
cous carcinoma, it was reported that high grade OSCCs 
had the highest overall mean of expression compared to 
low-grade OSCCs and verrucous carcinomas (17). The 
high expression of MMP-2 by tumour cells translates to 
greater degradation of basement membrane (BM) and 
extracellular matrix (ECM), thus providing channels 
that allow tumour cells to migrate and metastasize by 
direct spread and in vascular systems (18).
In contrast, a study from China (19), found that MMP-2 
expression was greater in the less aggressive verrucous 
carcinomas when compared with OSCC. In addition, 
they found no differences in MMP-2 expression among 
poor, moderately and well-differentiated OSCC. The-
se contradictory findings may be due to differences in 
techniques of tissue fixation and antigen retrieval. It is 
also possible that racial and genetic differences among 
varying sub-populations may influence expression of 
MMP-2 in different grades of OSCC.
MMP-8, unlike most other MMPs, has been shown to 
exhibit antitumor properties (20). Montel et al. (21) des-
cribed tumour spread inhibition by MMP-8 in animal 
breast cancer models. A high plasma level of MMP-8 
has been shown to be protective against lymph node me-
tastasis in breast cancer patients (8). A study reported 
that an elevated MMP-8 expression in tongue carcino-
ma cells was associated with an increased survival (22). 
On the contrary, Pradhan-Palikhe et al. (20) found that 
plasma MMP-8 levels did not predict survival in head 
and neck squamous cell carcinoma. Although the anti-
tumour and anti-invasive mechanisms of MMP-8 is not 
known with certainty, Korpi et al. (22) suggested that 
the protective role of MMP-8 may be related to its regu-
lation of estrogen receptor (ER) signalling, especially in 
hormone-regulated malignancies. Thus they suggested 
that its tumour inhibiting properties might be more pro-
nounced in females.  Although, we found no statistically 
significant difference in expression of MMP-8 between 
males and females, majority of the cases that expressed 
MMP-8 were seen in females. We also observed that ca-
ses that mildly expressed MMP-8 also strongly expres-
sed MMP-2 and this suggests a counteractive effect of 
MMP-2 and MMP-8 on each other.
The use of MMP inhibitors (MMPIs) in cancer thera-
py, though produced some encouraging results in vitro, 
were disappointing in clinical trials (23,24). These fa-
ilures have been attributed to the fact that some of these 
MMPIs may confer long-term side effects by disrupting 
some host-protective properties (23). Also, the fact that 
some MMPs (such as MMP-8) produced some anti-tu-
mour properties was not put into consideration in some 
of these previous treatments. However, the advent of se-
lective MMPIs (24-26) may help in resolving some of 
these downsides. It has also been suggested that the mo-
del of using biologic agents with molecularly targeted 
activity in selected cancer cases as in the use of trastu-
zumab (Herceptin) in HER-2/Neu positive breast cancer 
could also improve effectiveness of these MMPIs (26). 
This study showed that a higher proportion of poorly 
differentiated OSSC strongly expressed MMP-2 and 
strong expression of MMP-2 may correlate with aggres-
sion of OSCC. On the other hand, most cases did not ex-
press MMP-8 and moderate expression of MMP-8 was 
seen only in well differentiated OSCC. More so, MMP-8 
was expressed predominantly in females and eighty per-
cent of cases that express MMP-8 were females. We su-
ggest that using selective MMP-2 inhibitors in OSCC 
that strongly express MMP-2 may achieve better results 
than obtained from previous clinical trials of MMPIs in 
cancer therapy.
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